Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations

NCT02674750 is registered in ClinicalTrials.gov with Curis, Inc. as lead sponsor.

NCT NCT02674750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02674750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations
Lead sponsor
Curis, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2016
Completion date
May 28, 2019
Enrollment
70 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory diffuse large b-cell lymphoma including with myc alterations